KRAS and pachyonychia congenita: Kras mutations occur in more than 90% of PC cases [61]; constitutive activation of KrasG12D drives unrestrained proliferation and boosts survival of cancer cells [62], thus several strategies have been developed in order to inhibit the KRAS signalling pathway [63].